Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Curosurf (Poractant Alfa) Market Expected To Reach $ Billion By 2030 At % CAGR
The expansion observed in the historical timeframe was driven by a high number of preterm deliveries, the established effectiveness of surfactant therapy for respiratory distress syndrome (RDS), its broad implementation in neonatal intensive care units (NICUs), the backing of clinical protocols for surfactant treatment, and a decline in deaths among newborns.
The expansion observed during the forecast period is largely driven by rising global incidences of preterm births, the broadening of neonatal intensive care unit facilities, enhanced accessibility to neonatal care, growing consciousness regarding early respiratory distress syndrome treatment, and sustained clinical verification. Key developments shaping this future period encompass a greater prevalence of applications in neonatal intensive care, an increasing preference for synthetic surfactant usage, heightened emphasis on managing preterm deliveries, the establishment of consistent protocols for addressing respiratory distress syndrome, and the broader implementation of hospital-centric neonatal treatment approaches.
Download A Free Sample Report For Comprehensive Market Insights:
#Curosurf (Poractant Alfa) Market Growth Factors: Which Forces Are Supporting Market Expansion?
The rising occurrence of respiratory disorders is anticipated to drive expansion in the curosurf (poractant alfa) market in the coming period. These disorders, including asthma, COPD, and lung cancer, are common conditions impacting lung function and breathing, leading to difficulties in respiration and diminished pulmonary capacity. Their increasing prevalence stems from factors like worsening air pollution, which triggers asthma exacerbations, and a growing elderly population, which elevates rates of age-linked illnesses such as COPD. Poractant alfa, administered through an endotracheal tube, treats neonatal respiratory distress syndrome by enhancing lung performance and aiding breathing in preterm infants. As an example, the National Library of Medicine, a medical library in the US, projected in December 2023 that global chronic obstructive pulmonary disease (COPD) cases among individuals aged 25 and older would climb by 23% by 2050, hitting nearly 600 million. Consequently, the heightened frequency of respiratory disorders is fueling growth in the curosurf (poractant alfa) market.
Curosurf (Poractant Alfa) Market Driver: Growing Prevalence Of Premature Births Driving The Growth Of The Curosurf (Poractant Alfa) Market
An increasing rate of premature births is set to accelerate the expansion of the Curosurf (poractant alfa) market moving forward. These births happen before 37 weeks of gestation, while a typical full-term pregnancy lasts about 40 weeks. This trend is driven by older maternal ages and greater use of assisted reproductive technologies, which frequently result in multiple pregnancies. Poractant alfa is employed to manage respiratory distress syndrome in premature infants by decreasing lung surface tension, keeping the lungs open, and boosting oxygen exchange. For instance, the Office for National Statistics, a UK government body, reported in July 2025 that live births in England and Wales reached 594,677 in 2024—an uptick of 3,605 (0.6%) from the 591,072 recorded in 2023. Thus, the rising prevalence of premature births is propelling the Curosurf (poractant alfa) market forward.
Curosurf (Poractant Alfa) Market Segment Outlook: Which Categories Are Expanding The Fastest?
The curosurf (poractant alfa) market covered in this report is segmented –
1) By Type: Natural Poractant Alfa, Synthetic Poractant Alfa
2) By Sales Channel: Direct Sales, Distribution Channels, Online Marketplace
3) By Application: Pulmonary Edema, Respiratory Distress Syndrome, Other Respiratory Disorders
4) By End User: Hospitals, Clinics, Ambulance Services
Curosurf (Poractant Alfa) Market Industry Trends: What Changes Are Reshaping Demand?
Major players in the curosurf (poractant alfa) market are concentrating their efforts on creating advanced solutions, including new inhaled gene therapies designed to tackle unmet requirements in respiratory conditions. This innovative strategy, known as novel inhaled gene therapy, represents a state-of-the-art method where therapeutic genes are delivered straight to the lungs through inhalation, often using aerosolized particles or nanoparticles. A concrete example occurred in November 2024, when AlveoGene, a gene therapy firm from the UK, was granted Rare Pediatric Disease Designation (RPDD) by the FDA for AVG-002. This inhaled gene therapy targets lethal neonatal surfactant protein B (SP-B) deficiency, a serious genetic condition causing respiratory failure in newborns. SP-B deficiency results from mutations in the SFTPB gene and, at present, provides limited therapeutic avenues, with lung transplantation being the main option. AVG-002 leverages AlveoGene’s InGenuity platform to deliver a functional SP-B gene directly to lung tissue, and it has demonstrated encouraging outcomes in preclinical tests.
Curosurf (Poractant Alfa) Market Key Companies And Competitive Benchmarking
Major companies operating in the curosurf (poractant alfa) market are Chiesi Farmaceutici S.p.A
Access The Complete Curosurf (Poractant Alfa) Market Report:
Curosurf (Poractant Alfa) Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the curosurf (poractant alfa) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the curosurf (poractant alfa) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model